WO2001045694A1 - Urotensin-ii receptor antagonists - Google Patents

Urotensin-ii receptor antagonists Download PDF

Info

Publication number
WO2001045694A1
WO2001045694A1 PCT/US2000/034574 US0034574W WO0145694A1 WO 2001045694 A1 WO2001045694 A1 WO 2001045694A1 US 0034574 W US0034574 W US 0034574W WO 0145694 A1 WO0145694 A1 WO 0145694A1
Authority
WO
WIPO (PCT)
Prior art keywords
chloro
phenyl
ethoxy
dimethylamino
benzenesulfonamide
Prior art date
Application number
PCT/US2000/034574
Other languages
French (fr)
Inventor
Dashyant Dhanak
Steven D. Knight
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to CA002394603A priority Critical patent/CA2394603A1/en
Priority to AU24418/01A priority patent/AU2441801A/en
Priority to EP00988185A priority patent/EP1248607A4/en
Priority to JP2001546633A priority patent/JP2003518057A/en
Publication of WO2001045694A1 publication Critical patent/WO2001045694A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Definitions

  • the present invention relates to sulfonamides, pharmaceutical compositions containing them and their use as urotensin II antagonists
  • cardiovascular homeostasis The integrated control of cardiovascular homeostasis is achieved through a combination of both direct neuronal control and systemic neurohormonal activation. Although the resultant release of both contractile and relaxant factors is normally under stringent regulation, an aberration in this status quo can result in cardiohemodynamic dysfunction with pathological consequences.
  • the principal mammalian vasoactive factors that comprise this neurohumoral axis namely angiotensin-II, endothelin-1, norepinephrine, all function via an interaction with specific G-protein coupled receptors (GPCR).
  • GPCR G-protein coupled receptors
  • this peptide has significant hemodynamic and endocrine actions in diverse end-organ systems and tissues:
  • osmoregulation effects which include the modulation of transepithelial ion (Na + , Cl " ) transport.
  • Urotensin-II receptor may be useful in the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, (Hay DWP, Luttmann MA, Douglas SA: 2000, Br J Pharmacol: volume 131, pages 10-12) neurogenic inflammation and metabolic vasculopathies all of which are characterized by abnormal vasoconstriction and/or myocardial dysfunction. Since U-II and GPR14 are both expressed within the mammalian CNS (Ames et. al.
  • this invention provides for sulfonamides and pharmaceutical compositions containing them.
  • this invention provides for the use of sulfonamides as antagonists of urotensin II, and as inhibitors of urotensin II.
  • this invention provides for the use of sulfonamides for treating conditions associated with urotensin II imbalance.
  • this invention provides for the use of sulfonamides for the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, neurogenic inflammation and metabolic vasculopathies, addiction, schizophrenia, impulsivity, anxiety, stress, depression, neuromuscular function, and diabetes.
  • the urotensin antagonist may be administered alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, vasopeptidase inhibitors, diuretics, digoxin, and dual non-selective ⁇ -adrenoceptor and o - adrenoceptor antagonists.
  • agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, vasopeptidase inhibitors, diuretics, digoxin, and dual non-selective ⁇ -adrenoceptor and o - adrenoceptor antagonists.
  • ACE angiotensin converting enzyme
  • the present invention provides for compounds of Formula(I):
  • Ri is phenyl, benzothiophenyl, thienyl, furyl, pyrrolyl, pyridinyl, benzthiadiazoyl, benzoxadiazoyl, quinolinyl, or naphthyl, all of which may be substituted or unsubstituted by one, two, three, four or five of the following: halogen, methoxy, OH, NO2, YCF3, C ] _4 alkyl, C ( o_4)alkylC0 C ( o-4)alkyl, cyano, cycloQ ] _4)alkylenedioxy, or dimethylamino; R2 is halogen, CN or methyl;
  • R3 and R4 are independently hydrogen, C j_ 0 alkyl or benzyl; or with the nitrogen form a pyrrolidine or piperidine ring:
  • X is O or CH 2 ;
  • Y is a bond or O; provided the compound of Formula (I) is not 5-Chloro-3-methyl-benzo[b]thiophene-2- sulfonic acid [3-(2-dimethylamino-ethoxy)-4-iodo-phenyl]-amide; or a pharmaceutically acceptable salt thereof.
  • alkyl includes all straight chain and branched isomers. Representative examples thereof include methyl, ethyl, rc-propyl, wo-propyl, n-butyl, sec- butyl, w ⁇ -butyl, t-butyl, n-pentyl and n-hexyl.
  • Tialogen' and halo' include fluorine, chlorine, bromine and iodine and fluoro, chloro, bromo and iodo, respectively.
  • the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active form. All of these compounds and their diastereoisomers are contemplated to be within the scope of the present invention.
  • Ri is phenyl, thienyl, pyridinyl, benzthiadiazoyl, benzoxadiazoyl, or naphthyl, all of which may be substituted or unsubstituted by one, two, or three of the following: halogen, methoxy, NO2, YCF3, or C ] _4 alkyl.
  • R 2 is halogen
  • R3 is alkyl; more preferably R3 is methyl or ethyl.
  • R4 is alkyl; more preferably R4 is methyl or ethyl.
  • X is O.
  • Y is a bond.
  • Preferred Compounds are: N-[4-Iodo-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide;
  • More preferred compounds are: N-[4-Chloro-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide;
  • Compounds of Formula (I) and their pharmaceutically acceptable salts may be administered in a standard manner for the treatment of the indicated diseases, for example orally, parenterally, sub-lingually, transdermally, rectally, via inhalation or via buccal administration.
  • Compounds of Formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules and lozenges.
  • a syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used.
  • any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell.
  • Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil, or sesame oil.
  • a parenterally acceptable oil for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil, or sesame oil.
  • compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.
  • a typical suppository formulation comprises a compound of Formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa- butter or other low melting vegetable waxes or fats or their synthetic analogues.
  • Typical transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
  • the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to themselves a single dose.
  • Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid.
  • Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person.
  • a topical formulation contains suitably 0.01 to 1.0% of a compound of Formula
  • the daily dosage regimen for oral administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid.
  • the daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, of a compound of the Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid.
  • the daily dosage regimen for intranasal administration and oral inhalation is suitably about 10 to about 500 mg/person.
  • the active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity.
  • sulphonamide analogs may be used for the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, neurogenic inflammation and metabolic vasculopathies, addiction, schizophrenia, impulsivity, anxiety, stress, depression, neuromuscular function, and diabetes.
  • the urotensin antagonist may be administered alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, vasopeptidase inhibitors, diuretics, digoxin, and dual non-selective ⁇ -adrenoceptor and ⁇ j - adrenoceptor antagonists.
  • ACE angiotensin converting enzyme
  • HEK-293 cell membranes containing stable cloned human and rat GPR-14 (20 ug/assay) were incubated with 200 pM [1251] h-U-II (200 Ci/mmol " ' in the presence of increasing concentrations of test compounds in DMSO (0.1 nM to 10 uM), in a final incubation volume of 200 ul (20 mM Tris-HCl, 5 mM MgC12). Incubation was done for 30 minutes at room temperature followed by filtration GF/B filters with Brandel cell harvester.
  • a microtitre plate based Ca 2+ -mobilization FLIPR assay (Molecular Devices, Sunnyvale, CA) was used for the functional identification of the ligand activating HEK-293 cells expressing (stable) recombinant GPR-14.
  • the day following transfection cells were plated in a poly-D-lysine coated 96 well black/clear plates. After 18-24 hours the media was aspirated and Fluo 3AM-loaded cells were exposed to various concentrations (10 nM to 30 uM) of test compounds followed by h-U-II. After initiation of the assay, fluorescence was read every second for one minute and then every 3 seconds for the following one minute. The inhibitory concentration at 50% (IC50)was calculated for various test compounds.
  • Inositol phosphates assays HEK-293-GPR14 cells in T150 flask were prelabeled overnight with 1 uCi myo- H] inositol per ml of inositol free Dulbecco's modified Eagel's medium. After labeling, the cells were washed twice with Dulbecco's phosphate-buffered saline (DPBS) and then incubated in DPBS containing 10 mM LiCl for 10 in at 37°C.
  • DPBS Dulbecco's phosphate-buffered saline
  • the experiment was initiated by the addition of increasing concentrations of h-U-II (1 pM to l ⁇ M ) in the absence and presence of three different concentrations (0.3, 1 and 10 uM) of test compounds and the incubation continued for an additional 5 min at 37°C after which the reaction was terminated by the addition of 10% (final concentration) trichloroacetic acid and centrifugation.
  • the supernatants were neutralized with lOOul of 1M Trizma base and the inositol phosphates were separated on AG 1-X8 columns (0.8 ml packed, 100-200 mesh) in formate phase. Inositol monophosphate was eluted with 8 ml of 200 mM ammonium formate.
  • the mixture was filtered through Celite ® and the residue washed well with hot ethyl acetate.
  • the mixture was washed 2 x ethyl acetate, and the aqueous portion basified to pH 11 using solid potassium carbonate. It was extracted 2 x ethyl acetate, dried over magnesium sulfate, filtered, and concentrated to afford the product (1.53 g, 57%) as a rust-colored oil.
  • Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below. Tablets/Ingredients Per Tablet
  • Step 1 Blend ingredients No. 1, No. 2, No. 3 and No. 4 in a suitable mixer/blender.
  • Step 2 Add sufficient water portion-wise to the blend from Step 1 with careful mixing after each addition. Such additions of water and mixing until the mass is of a consistency to permit its conversion to wet granules.
  • Step 3 The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen.
  • Step 4 The wet granules are then dried in an oven at 140°F (60°C) until dry.
  • Step 5 The dry granules are lubricated with ingredient No. 5.
  • Step 6 The lubricated granules are compressed on a suitable tablet press.
  • a compound of Formula I (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
  • Parenteral Formulation A pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of formula I in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then sterilized by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

Abstract

The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.

Description

UROTENSIN-II RECEPTOR ANTAGONISTS
FIELD OF THE INVENTION
The present invention relates to sulfonamides, pharmaceutical compositions containing them and their use as urotensin II antagonists
BACKGROUND OF THE INVENTION
The integrated control of cardiovascular homeostasis is achieved through a combination of both direct neuronal control and systemic neurohormonal activation. Although the resultant release of both contractile and relaxant factors is normally under stringent regulation, an aberration in this status quo can result in cardiohemodynamic dysfunction with pathological consequences.
The principal mammalian vasoactive factors that comprise this neurohumoral axis, namely angiotensin-II, endothelin-1, norepinephrine, all function via an interaction with specific G-protein coupled receptors (GPCR). Urotensin-II, represents a novel member of this neurohumoral axis.
In the fish, this peptide has significant hemodynamic and endocrine actions in diverse end-organ systems and tissues:
• smooth muscle contraction both vascular and non-vascular in origin including smooth muscle preparations from the gastrointestinal tract, respiratory, and genitourinary tract. Both pressor and depressor activity has been described upon systemic administration of exogenous peptide
• osmoregulation: effects which include the modulation of transepithelial ion (Na+, Cl") transport.
Although a diuretic effect has been described, such an effect is postulated to be secondary to direct renovascular effects (elevated GFR)
• metabolism: urotensin-II influences prolactin secretion and exhibits a lipolytic effect in fish (activating triacylglycerol lipase resulting in the mobilization of non-esterified free fatty acids)
(Pearson, et. al. Proc. Natl. Acad. Sci. (U.S.A.) 1980, 77, 5021; Conlon, et. al. J. Exp. Zool. 1996, 275, 226.) In studies with human Urotensin-II it was found that it:
• was an extremely potent and efficacious vasoconstrictor
• exhibited sustained contractile activity that was extremely resistant to wash out
• had detrimental effects on cardiac performance (myocardial contractility) Human Urotensin-II was assessed for contractile activity in the rat-isolated aorta and was shown to be the most potent contractile agonist identified to date. Based on the in vitro pharmacology and in vivo hemodynamic profile of human Urotensin-II it plays a pathological role in cardiovascular diseases characterized by excessive or abnormal vasoconstriction and myocardial dysfunction. (Ames et. al. Nature 1999, 401, 282)
Compounds that antagonize the Urotensin-II receptor may be useful in the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, (Hay DWP, Luttmann MA, Douglas SA: 2000, Br J Pharmacol: volume 131, pages 10-12) neurogenic inflammation and metabolic vasculopathies all of which are characterized by abnormal vasoconstriction and/or myocardial dysfunction. Since U-II and GPR14 are both expressed within the mammalian CNS (Ames et. al. Nature 1999, 401, 282), they also may be useful in the treatment of addiction, schizophrenia, impulsivity, anxiety, stress, depression, and neuromuscular function. Functional U-II receptors are expressed in rhabdomyosarcomas cell lines and therefore may have oncological indications. Urotensin may also be implicated in various metabolic diseases such as diabetes (Ames et. al. Nature 1999, 401, 282, Nothacker et al., Nature Cell Biology 1 : 383-385, 1999)
SUMMARY OF THE INVENTION
In one aspect this invention provides for sulfonamides and pharmaceutical compositions containing them.
In a second aspect, this invention provides for the use of sulfonamides as antagonists of urotensin II, and as inhibitors of urotensin II.
In another aspect, this invention provides for the use of sulfonamides for treating conditions associated with urotensin II imbalance. In yet another aspect, this invention provides for the use of sulfonamides for the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, neurogenic inflammation and metabolic vasculopathies, addiction, schizophrenia, impulsivity, anxiety, stress, depression, neuromuscular function, and diabetes. The urotensin antagonist may be administered alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, vasopeptidase inhibitors, diuretics, digoxin, and dual non-selective β-adrenoceptor and o - adrenoceptor antagonists.
Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides for compounds of Formula(I):
Figure imgf000004_0001
wherein: Ri is phenyl, benzothiophenyl, thienyl, furyl, pyrrolyl, pyridinyl, benzthiadiazoyl, benzoxadiazoyl, quinolinyl, or naphthyl, all of which may be substituted or unsubstituted by one, two, three, four or five of the following: halogen, methoxy, OH, NO2, YCF3, C]_4 alkyl, C(o_4)alkylC0 C(o-4)alkyl, cyano, cycloQ ] _4)alkylenedioxy, or dimethylamino; R2 is halogen, CN or methyl;
R3 and R4 are independently hydrogen, C j_0 alkyl or benzyl; or with the nitrogen form a pyrrolidine or piperidine ring: X is O or CH2;
Y is a bond or O; provided the compound of Formula (I) is not 5-Chloro-3-methyl-benzo[b]thiophene-2- sulfonic acid [3-(2-dimethylamino-ethoxy)-4-iodo-phenyl]-amide; or a pharmaceutically acceptable salt thereof. When used herein, the term "alkyl" includes all straight chain and branched isomers. Representative examples thereof include methyl, ethyl, rc-propyl, wo-propyl, n-butyl, sec- butyl, wσ-butyl, t-butyl, n-pentyl and n-hexyl.
When used herein, the terms Tialogen' and halo' include fluorine, chlorine, bromine and iodine and fluoro, chloro, bromo and iodo, respectively.
The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active form. All of these compounds and their diastereoisomers are contemplated to be within the scope of the present invention.
Preferably Ri is phenyl, thienyl, pyridinyl, benzthiadiazoyl, benzoxadiazoyl, or naphthyl, all of which may be substituted or unsubstituted by one, two, or three of the following: halogen, methoxy, NO2, YCF3, or C]_4 alkyl.
Preferably R2 is halogen.
Preferably R3 is alkyl; more preferably R3 is methyl or ethyl. Preferably R4 is alkyl; more preferably R4 is methyl or ethyl.
Preferably X is O. Preferably Y is a bond.
Preferred Compounds are: N-[4-Iodo-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide;
4-Bromo-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
N-[4-Methyl-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide;
N-[4-Iodo-3-(2-dimethylamino-ethoxy)-phenyl]-3-methoxy-benzenesulfonamide;
N-[4-Bromo-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide; N-[4-Chloro-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide;
4,5-Dibromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide;
3,4-Dibromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,4,6-Trichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,6-Dichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-4-trifluoromethyl- benzenesulfonamide;
2-Bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-4,5-dimethoxy- benzenesulfonamide;
4-Bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
4-Iodo-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide; 3,5-Dichloro-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,3-Dichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
3-Chloro-4-fluoro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
3-Chloro-4-methyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide; 2,5-Dimethyl-4-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide;
2-Chloro-4-trifluoromethyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulf onamide ;
2,4-Dichloro-6-methyl-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulf onamide ;
3-Methoxy-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,5-Dimethoxy-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,5-Dimethoxy-N-[4-bromo-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
3-Nitro-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide; 2-Nitro-4-methoxy-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
3-Nitro-4-methyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2-Ethyl-4-bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
3,4-Dichlorophenyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,4,6-Trimethyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide; 4-Chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-naphthalenesulfonamide;
5-Chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide;
2,5-Dichloro-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-3-thiophenesulfonamide;
5-Bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide;
4,5-Dichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide; 5-({ [l-(4-Chloro-phenyl)-methanoyl]-amino}methyl)-N-[4-chloro-3-(2-dimethylamino- ethoxy)-phenyl]-2-thiophenesulfonamide;
N-[4-Iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzo[l,2,5]-4-thiadiazolesulfonamide;
2,4-Dichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2-Methyl-4-bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide; 2,6-Dimethyl-4-bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulf onamide;
3-Methoxy-4-bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulf onamide;
2,4-Dichloro-5-methyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide; 3-Nitro-4-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2-Nitro-4-trifluoromethyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulf onamide ;
5-Chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-l-naphthalenesulfonamide; 4-Bromo-5-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2- thiophenesulfonamide;
3-Bromo-5-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2- thiophenesulfonamide;
4-Nitro-5-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2- thiophenesulfonamide;
4,5-Dichloro-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide;
7-Chloro-N-f4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzo[l,2,5]oxadiazole-4- sulfonamide;
5-Bromo-6-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-3- pyridinesulf onamide ;
2,4-Dibromo-5-methoxy-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide;
2-Methyl-4,5-dimethoxy-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide; 2,6-Dimethyl-4-bromo-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]- benzenesulfonamide;
3,4-Dimethoxy-N-[4-chloro-3-(2-methylamino-ethoxy)-phenyl]-benzenesulfonamide;
2-Bromo-4,5-dimethoxy-N-[4-chloro-3-(2-methylamino-ethoxy)-phenyl]- benzenesulf onamide; 5-Chloro-N-f4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-naphthalenesulfonamide;
2,6-Dichloro-4-trifluoromethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]- benzenesulf onamide;
4,5-Dibromo-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide;
2-Bromo-4,5-dimethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]- benzenesulfonamide;
3,4-Dimethoxy-N-[4-chloro-3-(3-dimethylamino-propyl)-phenyl]-benzenesulfonamide;
3,4-Dimethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2-Chloro-4,5-dimethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]- benzenesulf onamide; and 2-Chloro-4,5-dimethoxy-N-[4-chloro-3-(2-dimethylarnino-ethoxy)-phenyl]- benzenesulfonamide.
More preferred compounds are: N-[4-Chloro-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide;
4,5-Dibromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide;
3,4-Dibromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,4,6-Trichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,6-Dichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-4-trifluoromethyl- benzenesulfonamide;
N-[4-Iodo-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide;
2-Bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyI]-4,5-dimethoxy- benzenesulf onamide;
2,4-Dichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide; 2-Methyl-4-bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,6-Dimethyl-4-bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulf onamide;
3-Methoxy-4-bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide; 2,4-Dichloro-5-methyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide;
3-Nitro-4-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2-Nitro-4-trifluoromethyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulf onamide; 4-Chlorophenyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
5-Chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-l-naphthalenesulfonamide;
4-Bromo-5-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2- thiophenesulf onamide ;
3-Bromo-5-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2- thiophenesulfonamide;
4-Nitro-5-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2- thiophenesulfonamide;
4,5-Dichloro-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-2 -thiophenesulfonamide;
7-Chloro-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzo[l,2,5]oxadiazole-4- sulfonamide; 5-Bromo-6-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-3- pyridinesulf onamide;
2,4-Dibromo-5-methoxy-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide; 2-Methyl-4,5-dimethoxy-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide;
2,6-Dichloro-4-trifluoromethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]- benzenesulfonamide;
4,5-Dibromo-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide; 2-Bromo-4,5-dimethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]- benzenesulf onamide;
3,4-Dimethoxy-N-[4-chloro-3-(3-dimethylamino-propyl)-phenyl]-benzenesulfonamide;
3,4-Dimethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2-Chloro-4,5-dimethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]- benzenesulfonamide; and
2-Chloro-4,5-dimethoxy-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide.
Compounds of Formula (I) were prepared as outlined in Scheme 1.
Scheme 1
Figure imgf000009_0001
Figure imgf000009_0002
3 Conditions: a) ClCH2CH2NR3R4-hydrochloride, potassium carbonate, water/1,2- dimethoxyethane, reflux; b) HCl; c) R1 SO2CI, CHCl3, ambient temperature. (Rj, R3 and R4 as defined above) For example, phenol 1 was alkylated with various dialkylaminoethyl chlorides and the resulting ethers deprotected to provide the anilines 2. Subsequent sulfonylation of the anilines furnished the target compounds 3.
With appropriate manipulation, including the use of alternative nitrogen protecting group(s), the synthesis of the remaining compounds of Formula (I) was accomplished by methods analogous to those above and to those described in the Experimental section.
In order to use a compound of the Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
Compounds of Formula (I) and their pharmaceutically acceptable salts may be administered in a standard manner for the treatment of the indicated diseases, for example orally, parenterally, sub-lingually, transdermally, rectally, via inhalation or via buccal administration. Compounds of Formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules and lozenges. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used.
Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, agar, pectin, acacia, stearic acid, starch, lactose and sucrose. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell.
Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil, or sesame oil.
Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane. A typical suppository formulation comprises a compound of Formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa- butter or other low melting vegetable waxes or fats or their synthetic analogues. Typical transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to themselves a single dose. Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person. A topical formulation contains suitably 0.01 to 1.0% of a compound of Formula
(I).
The daily dosage regimen for oral administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, of a compound of the Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for intranasal administration and oral inhalation is suitably about 10 to about 500 mg/person. The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity. These sulphonamide analogs may be used for the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, neurogenic inflammation and metabolic vasculopathies, addiction, schizophrenia, impulsivity, anxiety, stress, depression, neuromuscular function, and diabetes. The urotensin antagonist may be administered alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, vasopeptidase inhibitors, diuretics, digoxin, and dual non-selective β-adrenoceptor and αj- adrenoceptor antagonists. No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.
The biological activity of the compounds of Formula (I) are demonstrated by the following tests:
Radioligand binding:
HEK-293 cell membranes containing stable cloned human and rat GPR-14 (20 ug/assay) were incubated with 200 pM [1251] h-U-II (200 Ci/mmol"' in the presence of increasing concentrations of test compounds in DMSO (0.1 nM to 10 uM), in a final incubation volume of 200 ul (20 mM Tris-HCl, 5 mM MgC12). Incubation was done for 30 minutes at room temperature followed by filtration GF/B filters with Brandel cell harvester.
125j labeled U-II binding was quantitated by gamma counting. Nonspecific binding was defined by ^5j U-II binding in the presence of 100 nM of unlabeled human U-II. Analysis of the data was performed by nonlinear least square fitting. Ca2+-mobilization:
A microtitre plate based Ca2+-mobilization FLIPR assay (Molecular Devices, Sunnyvale, CA) was used for the functional identification of the ligand activating HEK-293 cells expressing (stable) recombinant GPR-14. The day following transfection, cells were plated in a poly-D-lysine coated 96 well black/clear plates. After 18-24 hours the media was aspirated and Fluo 3AM-loaded cells were exposed to various concentrations (10 nM to 30 uM) of test compounds followed by h-U-II. After initiation of the assay, fluorescence was read every second for one minute and then every 3 seconds for the following one minute. The inhibitory concentration at 50% (IC50)was calculated for various test compounds. Inositol phosphates assays: HEK-293-GPR14 cells in T150 flask were prelabeled overnight with 1 uCi myo- H] inositol per ml of inositol free Dulbecco's modified Eagel's medium. After labeling, the cells were washed twice with Dulbecco's phosphate-buffered saline (DPBS) and then incubated in DPBS containing 10 mM LiCl for 10 in at 37°C. The experiment was initiated by the addition of increasing concentrations of h-U-II (1 pM to lμM ) in the absence and presence of three different concentrations (0.3, 1 and 10 uM) of test compounds and the incubation continued for an additional 5 min at 37°C after which the reaction was terminated by the addition of 10% (final concentration) trichloroacetic acid and centrifugation. The supernatants were neutralized with lOOul of 1M Trizma base and the inositol phosphates were separated on AG 1-X8 columns (0.8 ml packed, 100-200 mesh) in formate phase. Inositol monophosphate was eluted with 8 ml of 200 mM ammonium formate. Combined inositol di and tris phosphate was eluted with 4ml of 1M ammonium formate/ 0.1 M formic acid. Eluted fractions were counted in beta scintillation counter. Based on shift from the control curve KB was calculated. Activity for the compounds of this invention range from (radioligand binding assay): Ki = 50 nM - 10000 nM (example 8 Ki = 1300 nM)
The following Examples are illustrative but not limiting embodiments of the present invention.
Example 1 N-r4-Chloro-3-(2-dimethylamino-ethoxy)phenyll-3,4-dimethoxy-benzenesulfonamide
Figure imgf000013_0001
a). 2-Chloro-5-aminophenol
2-Chloro-5-nitroanisole (310 g, 1.7 mol) was taken up in a mixture of 48% HBr (1.5 L) and AcOH (1.2 L) and heated at reflux for 3 days. The dark solution was allowed to cool to room temperature, poured into ice water (10 L), and let stand for 3 h. The resultant dull yellow solid was filtered, washed with water, and dried in vacuo (230 g, 79%): mp 1 15- 1 17°C.
b). 2-Chloro-5-aminophenol A solution of 2-chloro-5-nitrophenol (25 g, 0.14 mol) in ethyl acetate (150 mL) was treated with 5% Pt/C (250mg) and the mixture shaken under a hydrogen atmosphere (30 psi) for 4h.
The mixture was filtered through Celite® and the residue washed well with hot ethyl acetate.
The filtrate was treated with activated charcoal and re-filtered as above. Evaporation of the ethyl acetate gave a solid (19.8 g, 98%).
c). 4-Chloro-3-hydroxyphenylcarbamic acid tert-butyl ester
To a solution of 2-chloro-5-aminophenol (20 g, 0.14 mol) in THF (150 mL) was added a solution of di-ferr-butyl dicarbonate (33 g, 0.15 mol) in THF (150 mL). The reaction was heated at reflux for 6 h, at which time it was allowed to cool to room temperature. The solvent was removed in vacuo and the residue diluted with ether (500 mL) and washed with
1 M citric acid (2 x 300 mL). The aqueous washings were extracted with ether (300 mL) and the combined organics washed with brine (300 mL), dried (MgS04), and concentrated. The resultant brown solid was triturated with hexanes and dried in vacuo to give 33 g (97%) of the title compound: mp 103-106 °C.
d). 3-[2-(N,N-Dimethylamino)ethoxy]-4-chloroaniline To a solution of 4-chloro-3-hydroxyphenylcarbamic acid tert-butyl ester (140 mg, 0.57 mmol) in 4:1 DME/water (5 mL) was added dimethylaminoethyl chloride hydrochloride (90 mg, 0.63 mmol) and K2C03 (320 mg, 2.3 mmol). The reaction mixture was heated at reflux for 16 h, at which time it was allowed to cool to room temperature. The DME was removed in vacuo and the residue treated with 6 N HCl (2 mL). The resultant mixture was stirred at room temperature for 2 h, at which time it was diluted with water (5 mL) and washed with EtOAc (5 mL). The aqueous layer was basified with solid K2C03 and extracted with EtOAc (2 x 10 mL). The EtOAc layers were washed with brine (10 mL), dried (MgS0 ), and concentrated to give 60 mg (50%) of the title compound.
e). N-[4-Chloro-3-(2-dimethylamino-ethoxy)phenyl]-3,4-dimethoxy-benzenesulfonamide 3-[2-(N,N-Dimethylamino)ethoxy]-4-chloroaniline (l.OOg, 4.66 mmol) was dissolved in 15 mL CHCI3. A solution of 3,4-dimethoxybenzenesulfonyl chloride (1.1 Og, 4.66 mmol) in 14 mL CHCI3 was added and the solution was allowed to stir overnight. Diethyl ether was added to the cloudy white mixture and the white product (1.97g, 94%) was filtered and dried. Recrystallisation from hot methanol gave sparkling white crystals which were filtered and dried: mp 228-229°C; MS (ES+) m/e 415 [M+H]+
The compounds of Examples 2 - 6 were prepared by using the general procedure(s) of
Example 1 above with appropriate substitution of reactants:
Example 2
4,5-Dibromo-thiophene-2-sulfonic acid [4-chloro-3-(2-dimethylamino-ethoxy)-phenvn- amide.
Figure imgf000014_0001
Prepared from 4,5-dibromo-thiophene-2-sulfonyl chloride and 3-[2-(N,N- dimethylamino)ethoxy]-4-chloroaniline. MS (ES+) m/e 517 [M+H]+. Example 3
3,4-Dibromo-N-r4-chloro-3-(2-dimethylamino-ethoxy)-phenyll-benzenesulfonamide.
Figure imgf000015_0001
Prepared from 3,4-dibromobenzenesulfonyl chloride and 3-[2-(N,N- dimethylamino)ethoxy]-4-chloroaniline. MS (ES+) m/e 511 [M+H]+.
Example 4
2,4,6-Trichloro-N-r4-chloro-3-(2-dimethylamino-ethoxy)-phenyll-benzenesulfonamide.
Figure imgf000015_0002
Prepared from 2,4,6-trichlorobenzenesulfonyl chloride and 3-[2-(N,N- dimethylamino)ethoxy]-4-chloroaniline. MS (ES+) m e 457 [M+H]+
Example 5
2,6-Dichloro-N- 4-chloro-3-(2-dimethylamino-ethoxy)-phenyll-4-trifluoromethyl- benzenesulf onamide.
Figure imgf000015_0003
Prepared from 2,6-Dichloro-4-trifluoromethylbenzenesulfonyl chloride and 3-[2-(N,N- dimethylamino)ethoxy]-4-chloroaniline. MS (ES+) m/e 491 [M+H]+
Example 6
N-[3-(2-Dimethylamino-ethoxy)-4-iodo-phenyn-3,4-dimethoxy-benzenesulfonamide.
Figure imgf000015_0004
a) . N-[3-(2-Dimethylamino-ethoxy)-4-iodo-phenyl]-acetamide
2-Iodo-5-acetamidophenol (2.15 g, 7.76 mmol) was dissolved in 1,2- dimethoxyethane (30 mL). 2-Dimethylaminoethyl chloride hydrochloride (1 eq, 7.76 mmol, 1.12 g) was added, followed by a solution of potassium carbonate (4 eq, 31.0 mmol, 4.30 g) in water (8 mL). The solution was heated to reflux, stirring at this temperature for 22 hours. The 1 ,2-dimethoxyethane was evaporated in vacuo and the residue was acidified to pH 1 using 3N hydrochloric acid. The mixture was washed 2 x ethyl acetate, and the aqueous portion basified to pH 11 using solid potassium carbonate. It was extracted 2 x ethyl acetate, dried over magnesium sulfate, filtered, and concentrated to afford the product (1.53 g, 57%) as a rust-colored oil.
MS (ES+) m/e 349 [M+H]+
b). 3-(2-Dimethylamino-ethoxy)-4-iodo-phenylamine
To a solution of the compound of Example 1(a) (1.52 g, 4.39 mmol) in ethanol (22 mL) was added 10% aqueous sodium hydroxide solution (29 mL). The mixture was heated to reflux and allowed to stir at this temperature for 16 hours. It was cooled to room temperature and concentrated in vacuo. The residue was extracted 2 x ethyl acetate, dried over magnesium sulfate, filtered, and concentrated to furnish the product (1.13 g, 84%) as a rust-colored oil which solidified upon standing. MS (ES+) m/e 307 [M+H]+
c). N-[3-(2-Dimethylamino-ethoxy)-4-iodo-phenyl]-3,4-dimethoxy-benzenesulfonamide To a solution of the compound of Example 1(b) (0.25 g, 0.81 mmol) in N,N- dimethylformamide (4 mL) was added 3,4-dimethoxybenzenesulfonyl chloride (1 eq, 0.81 mmol, 0.19 g). The pale orange solution was allowed to stir at room temperature for 23 hours. The crude product was purified via Gilson HPLC purification (10-90% acetonitrile/water over 5 minutes) and lyophilized overnight. The resulting hydochloride salt was azeotroped 1 x methanol and 1 x methylene chloride to furnish the product (0.16 g,
35%) as a fluffy white solid. MS (ES+) m/e 507 (M+H)+ Example 7
2-Bromo-N-r4-chloro-3-(2-dimethylamino-ethoxy)-phenyll-4,5-dimethoxy- benzenesulfonamide
Figure imgf000017_0001
a). 2-Bromo-4,5-dimethoxy-benzenesulfonyl chloride.
To a cooled (0 °C) solution of 4-bromoveratrole (15 mL, 100 mmol) in methylene chloride (100 mL) was added dropwise over 30 minutes chlorosulfonic acid (26 mL, 400 mmol). The resultant solution was allowed to warm to ambient temperature, maintained at this temperature for 3 hours, and then partitioned into a 1:1 methylene chloride/ice water mixture (500 mL). The organic layer was washed with water (2 x 200 mL) and brine (200 mL), dried (magnesium sulfate), and concentrated to give 2-bromo-4,5- dimethoxybenzenesulfonyl chloride (25 g, 78% yield) as a grey solid.
b). 2-Bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-4,5-dimethoxy- benzenesulf onamide.
Prepared from 2-bromo-4,5-dimethoxy-benzenesulfonyl chloride and 3-[2-(N,N- dimethylamino)ethoxy]-4-chloroaniline using the general procedure of Example IE above.
MS (ES+) m/e 494 [M+H]+
Figure imgf000017_0002
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
EXAMPLE 119
Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below. Tablets/Ingredients Per Tablet
1.Active ingredient 40 mg (Cpd of Form. I)
2.Corn Starch 20 mg 3.Alginic acid 20 mg
4. Sodium Alginate 20 mg
5.Mg stearate 1.3 mg
2.3 mg
Procedure for tablets:
Step 1 : Blend ingredients No. 1, No. 2, No. 3 and No. 4 in a suitable mixer/blender. Step 2: Add sufficient water portion-wise to the blend from Step 1 with careful mixing after each addition. Such additions of water and mixing until the mass is of a consistency to permit its conversion to wet granules. Step 3: The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen.
Step 4: The wet granules are then dried in an oven at 140°F (60°C) until dry. Step 5: The dry granules are lubricated with ingredient No. 5. Step 6: The lubricated granules are compressed on a suitable tablet press.
Inhalant Formulation
A compound of Formula I, (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use. Parenteral Formulation A pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of formula I in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then sterilized by filtration through a 0.22 micron membrane filter and sealed in sterile containers.
The above specification and Examples fully disclose how to make and use the compounds of the present invention. However, the present invention is not limited to the particular embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims. The various references to journals, patents and other publications which are cited herein comprise the state of the art and are incorporated herein by reference as though fully set forth.

Claims

What is claimed is:
Figure imgf000032_0001
wherein:
Rj is phenyl, benzothiophenyl, thienyl, furyl, pyrrolyl, pyridinyl, benzthiadiazoyl, benzoxadiazoyl, quinolinyl, or naphthyl, all of which may be substituted or unsubstituted by one, two, three, four or five of the following: halogen, methoxy, OH, NO2, YCF3, Cj.4 alkyl, C(o_4)alkylCO2C(o_4)alkyl, cyano, cycloC( ]_4)alkylenedioxy, or dimethylamino;
R2 is halogen, CN or methyl;
R3 and R4 are independently hydrogen, Cj.β alkyl or benzyl; or with the nitrogen form a pyrrolidine or piperidine ring; X is O or CH2; Y is a bond or O; provided the compound of Formula (I) is not 5-Chloro-3-methyl-benzo[b]thiophene-2- sulfonic acid [3-(2-dimethylamino-ethoxy)-4-iodo-phenyl]-amide; or a pharmaceutically acceptable salt thereof.
2. A compound according to Claim 1 wherein R] is phenyl, thienyl, pyridinyl, benzthiadiazoyl, benzoxadiazoyl, or naphthyl, all of which may be substituted or unsubstituted by one, two, or three of the following: halogen, methoxy, N02, YCF3, or C]_
4 alkyl; R2 is halogen; R3 is alkyl; R4 is alkyl; X is O, and Y is a bond.
3. A compound according to Claim 1 wherein R] is Rj is phenyl, thienyl, pyridinyl, benzthiadiazoyl, benzoxadiazoyl, or naphthyl, all of which may be substituted or unsubstituted by one, two, or three of the following: halogen, methoxy, N02, YCF3, or Cj_
4 alkyl; R2 is halogen; R3 is methyl or ethyl; R4 is methyl or ethyl; X is O, and Y is a bond.
4. A compound according to claim 1 chosen from the group consisting of:
N-[4-Iodo-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide;
4-Bromo-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
N-[4-Methyl-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide; N-[4-Iodo-3-(2-dimethylamino-ethoxy)-phenyl]-3-methoxy-benzenesulfonamide;
N-[4-Bromo-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide;
N-[4-Chloro-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide;
4,5-Dibromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide;
3,4-Dibromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide; 2,4,6-Trichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,6-Dichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-4-trifluoromethyl- benzenesulfonamide ;
2-Bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-4,5-dimethoxy- benzenesulf onamide; 4-Bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
4-Iodo-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
3,5-Dichloro-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,3-Dichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
3-Chloro-4-fluoro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide; 3-Chloro-4-methyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,5-Dimethyl-4-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide;
2-Chloro-4-trifluoromethyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulf onamide ; 2,4-Dichloro-6-methyl-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide ;
3-Methoxy-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,5-Dimethoxy-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,5-Dimethoxy-N-[4-bromo-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide; 3-Nitro-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2-Nitro-4-methoxy-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulf onamide;
3-Nitro-4-methyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2-Ethyl-4-bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
3,4-Dichlorophenyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide; 2,4,6-Trimethyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide; 4-Chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-naphthalenesulfonamide;
5-Chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide;
2,5-Dichloro-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-3-thiophenesulfonamide;
5-Bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide; 4,5-Dichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide;
5-({ [l-(4-Chloro-phenyl)-methanoyl3-amino}methyl)-N-[4-chloro-3-(2-dimethylamino- ethoxy)-phenyl]-2-thiophenesulfonamide;
N-[4-Iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzo[l,2,5]-4-thiadiazolesulfonamide;
2,4-Dichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide; 2-Methyl-4-bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,6-Dimethyl-4-bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulf onamide ;
3-Methoxy-4-bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide; 2,4-Dichloro-5-methyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide;
3-Nitro-4-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2-Nitro-4-trifluoromethyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide; 5-Chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-l -naphthalenesulfonamide;
4-Bromo-5-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2- thiophenesulf onamide;
3-Bromo-5-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2- thiophenesulfonamide; 4-Nitro-5-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2- thiophenesulf onamide ;
4,5-Dichloro-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide;
7-Chloro-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzo[l,2,5]oxadiazole-4- sulf onamide; 5-Bromo-6-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-3- pyridinesulfonamide;
2,4-Dibromo-5-methoxy-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulf onamide ;
2-Methyl-4,5-dimethoxy-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide; 2,6-Dimethyl-4-bromo-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]- benzenesulfonamide;
3,4-Dimethoxy-N-[4-chloro-3-(2-methylamino-ethoxy)-phenyl]-benzenesulfonamide;
2-Bromo-4,5-dimethoxy-N-[4-chloro-3-(2-methylamino-ethoxy)-phenyl]- benzenesulfonamide;
5-Chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-naphthalenesulfonamide;
2,6-Dichloro-4-trifluoromethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]- benzenesulfonamide;
4,5-Dibromo-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide; 2-Bromo-4,5-dimethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]- benzenesulf onamide ;
3,4-Dimethoxy-N-[4-chloro-3-(3-dimethylamino-propyl)-phenyl]-benzenesulfonamide;
3,4-Dimethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2-Chloro-4,5-dimethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]- benzenesulfonamide; and
2-Chloro-4,5-dimethoxy-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide.
5. A compund of Claim 1 chosen from the group consisting of: N-[4-Chloro-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide;
4,5-Dibromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide;
3,4-Dibromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,4,6-Trichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,6-Dichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-4-trifluoromethyl- benzenesulfonamide;
N-[4-Iodo-3-(2-dimethylamino-ethoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide;
2-Bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-4,5-dimethoxy- benzenesulfonamide;
2,4-Dichloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide; 2-Methyl-4-bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2,6-Dimethyl-4-bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide;
3-Methoxy-4-bromo-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide; 2,4-Dichloro-5-methyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide;
3-Nitro-4-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
2-Nitro-4-trifluoromethyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide;
4-Chlorophenyl-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-benzenesulfonamide;
5-Chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-l-naphthalenesulfonamide;
4-Bromo-5-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2- thi ophenesulf onamide ; 3-Bromo-5-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2- thiophenesulfonamide ;
4-Nitro-5-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-2- thi ophenesulf onamide ;
4,5-Dichloro-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide; 7-Chloro-N-[4-iodo-3-(2-dimethylamino-ethoxy)-phenyl]-benzo[l,2,5]oxadiazole-4- sulfonamide;
5-Bromo-6-chloro-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]-3- pyridinesulfonamide;
2,4-Dibromo-5-methoxy-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide;
2-Methyl-4,5-dimethoxy-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide;
2,6-Dichloro-4-trifluoromethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]- benzenesulf onamide ; 4,5-Dibromo-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]-2-thiophenesulfonamide;
2-Bromo-4,5-dimethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]- benzenesulfonamide;
3,4-Dimethoxy-N-[4-chloro-3-(3-dimethylamino-propyl)-phenyl]-benzenesulfonamide;
3,4-Dimethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]-benzenesulfonamide; 2-Chloro-4,5-dimethoxy-N-[4-chloro-3-(2-diethylamino-ethoxy)-phenyl]- benzenesulfonamide; and
2-Chloro-4,5-dimethoxy-N-[4-chloro-3-(2-dimethylamino-ethoxy)-phenyl]- benzenesulfonamide.
6. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.
7. A method of treating conditions associated with Urotensin-II imbalance by antagonizing the Urotensin-II receptor which comprises administering to a patient in need thereof, a compound of Formula I of claim 1.
8. A method according to Claim 7 wherein the disease is congestive heart failure, stroke, ischemic heart disease, angina, myocardial ischemia, cardiac arrythmias, essential hypertension, pulmonary hypertension, COPD, restenosis, asthma, neurogenic inflammation metabolic vasculopathies, addiction, schizophrenia, impulsivity, anxiety, stress, depression, neuromuscular function, or diabetes.
9. A process for preparing a compound of formula (I) of claim 1 by
a) alkylating a compound of formula (II):
BOCNH
Figure imgf000037_0001
II wherein R2 is halogen, CN or methyl; with a dialkyl amino ethyl chloride; b) deprotecting to provide a compound of formula (III):
Figure imgf000037_0002
III wherein R3 and R4 are independently hydrogen, Cj.g alkyl or benzyl; or with the nitrogen form a pyrrolidine or piperidine ring; and c) subsequent sulfonylation to provide a compound of formula (I):
Figure imgf000038_0001
wherein RI, R2, R3, and R4 are as defined in Claim 1.
PCT/US2000/034574 1999-12-21 2000-12-19 Urotensin-ii receptor antagonists WO2001045694A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002394603A CA2394603A1 (en) 1999-12-21 2000-12-19 Urotensin-ii receptor antagonists
AU24418/01A AU2441801A (en) 1999-12-21 2000-12-19 Urotensin-ii receptor antagonists
EP00988185A EP1248607A4 (en) 1999-12-21 2000-12-19 Urotensin-ii receptor antagonists
JP2001546633A JP2003518057A (en) 1999-12-21 2000-12-19 Urotensin-II receptor antagonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17280799P 1999-12-21 1999-12-21
US60/172,807 1999-12-21

Publications (1)

Publication Number Publication Date
WO2001045694A1 true WO2001045694A1 (en) 2001-06-28

Family

ID=22629329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/034574 WO2001045694A1 (en) 1999-12-21 2000-12-19 Urotensin-ii receptor antagonists

Country Status (5)

Country Link
EP (1) EP1248607A4 (en)
JP (1) JP2003518057A (en)
AU (1) AU2441801A (en)
CA (1) CA2394603A1 (en)
WO (1) WO2001045694A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002015934A1 (en) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Preventives and remedies for central nervous system diseases
WO2002076979A1 (en) * 2001-03-27 2002-10-03 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
WO2002078641A2 (en) * 2001-03-29 2002-10-10 Smithkline Beecham Corporation Pyrrolidine sulfonamides
WO2002090337A1 (en) * 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
EP1310490A1 (en) * 2000-07-04 2003-05-14 Takeda Chemical Industries, Ltd. Gpr14 antagonist
WO2004007472A1 (en) * 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
EP1385495A2 (en) * 2001-05-07 2004-02-04 SmithKline Beecham Corporation Sulfonamides
EP1387679A1 (en) * 2001-05-07 2004-02-11 SmithKline Beecham Corporation Sulfonamides
EP1399137A1 (en) * 2001-05-07 2004-03-24 SmithKline Beecham Corporation Sulfonamides
WO2004031181A1 (en) * 2002-10-07 2004-04-15 Glaxo Group Limited Sulfonamide derivatives as antipsychotic agents
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
US7375227B2 (en) 2001-12-04 2008-05-20 Actelion Pharmaceuticals Ltd. Quinoline derivatives
US7750161B2 (en) 2003-09-26 2010-07-06 Daniel Bur Pyridine derivatives
WO2010048332A3 (en) * 2008-10-22 2010-07-22 Acucela, Inc. Compounds for treating ophthalmic diseases and disorders
US8067601B2 (en) 2004-10-12 2011-11-29 Actelion Pharmaceticals Ltd. 1-[2-(4-benzyl-4-hydroxy-piperidin-1 -yl )-ethyl]-3-(2-methyl-quinolin- 4-yl)- urea as crystalline sulfate salt

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795892A (en) * 1994-08-30 1998-08-18 Boehringer Manneim Gmbh 4-aminopyridazines, method of preparing them and drugs containing these compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (en) * 1996-12-19 2002-12-28 Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795892A (en) * 1994-08-30 1998-08-18 Boehringer Manneim Gmbh 4-aminopyridazines, method of preparing them and drugs containing these compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1248607A4 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1310490A1 (en) * 2000-07-04 2003-05-14 Takeda Chemical Industries, Ltd. Gpr14 antagonist
EP1310490A4 (en) * 2000-07-04 2004-03-17 Takeda Chemical Industries Ltd Gpr14 antagonist
WO2002015934A1 (en) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Preventives and remedies for central nervous system diseases
WO2002076979A1 (en) * 2001-03-27 2002-10-03 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
US6815451B2 (en) 2001-03-27 2004-11-09 Actelion Pharmaceuticals Ltd. 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists
WO2002078641A3 (en) * 2001-03-29 2002-11-28 Smithkline Beecham Corp Pyrrolidine sulfonamides
WO2002078641A2 (en) * 2001-03-29 2002-10-10 Smithkline Beecham Corporation Pyrrolidine sulfonamides
WO2002090337A1 (en) * 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
EP1385495A4 (en) * 2001-05-07 2005-12-21 Smithkline Beecham Corp Sulfonamides
EP1385495A2 (en) * 2001-05-07 2004-02-04 SmithKline Beecham Corporation Sulfonamides
EP1387679A1 (en) * 2001-05-07 2004-02-11 SmithKline Beecham Corporation Sulfonamides
EP1399137A1 (en) * 2001-05-07 2004-03-24 SmithKline Beecham Corporation Sulfonamides
EP1387679A4 (en) * 2001-05-07 2004-08-11 Smithkline Beecham Corp Sulfonamides
EP1399137A4 (en) * 2001-05-07 2005-12-14 Smithkline Beecham Corp Sulfonamides
US7375227B2 (en) 2001-12-04 2008-05-20 Actelion Pharmaceuticals Ltd. Quinoline derivatives
WO2004007472A1 (en) * 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
US7122538B2 (en) 2002-10-07 2006-10-17 Glaxo Group Limited Sulfonamide derivatives as antipsychotic agents
WO2004031181A1 (en) * 2002-10-07 2004-04-15 Glaxo Group Limited Sulfonamide derivatives as antipsychotic agents
US7750161B2 (en) 2003-09-26 2010-07-06 Daniel Bur Pyridine derivatives
US8067601B2 (en) 2004-10-12 2011-11-29 Actelion Pharmaceticals Ltd. 1-[2-(4-benzyl-4-hydroxy-piperidin-1 -yl )-ethyl]-3-(2-methyl-quinolin- 4-yl)- urea as crystalline sulfate salt
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
WO2007076875A3 (en) * 2006-01-06 2007-11-15 Univ Aarhus Compounds acting on the serotonin transporter
WO2010048332A3 (en) * 2008-10-22 2010-07-22 Acucela, Inc. Compounds for treating ophthalmic diseases and disorders
US8674137B2 (en) 2008-10-22 2014-03-18 Acucela Inc. Compounds for treating ophthalmic diseases and disorders
US9193669B2 (en) 2008-10-22 2015-11-24 Acucela Inc. Compounds for treating ophthalmic diseases and disorders

Also Published As

Publication number Publication date
EP1248607A1 (en) 2002-10-16
CA2394603A1 (en) 2001-06-28
EP1248607A4 (en) 2004-10-06
AU2441801A (en) 2001-07-03
JP2003518057A (en) 2003-06-03

Similar Documents

Publication Publication Date Title
EP1385840B1 (en) Sulfonamides
US20040198979A1 (en) Sulfonamides
US6849635B2 (en) Sulfonamides
WO2001045694A1 (en) Urotensin-ii receptor antagonists
WO2002079155A1 (en) Pyrrolidine sulfonamides
US7019008B2 (en) Pyrrolidine sulfonamides
WO2002090353A1 (en) Sulfonamides
WO2002089740A2 (en) Sulfonamides
US20030100580A1 (en) Urotensin-II receptor antagonists
EP1385830A1 (en) Sulfonamides
US20040082566A1 (en) Pyrrolidine sulfonamides
WO2004043369A2 (en) Sulfonamides
WO2002078641A2 (en) Pyrrolidine sulfonamides
WO2004043368A2 (en) Sulfonamides
WO2004043948A1 (en) Sulfonamides
EP1381365A1 (en) Pyrrolidine sulfonamides
US20040142948A1 (en) Sulfonamides
US20040152895A1 (en) Sulfonamides
AU2002303678A1 (en) Sulfonamides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AU BA BB BG BR BZ CA CN CZ DZ EE GE GH GM HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO SG SI SK SL TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10149794

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2394603

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000988185

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 546633

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000988185

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000988185

Country of ref document: EP